(Sharecast News) - Drugmaker GSK said on Tuesday that it would pay up to $750m to acquire full global rights to a trispecific T‑cell engager for multiple myeloma from privately held biotechnology company Chimagen Biosciences.
GSK stated the agreement includes an upfront payment and further development and commercial milestones, with the...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE